Nasdaq Cmmb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories....

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14, Zacks reports. During the same period in the previous year, the firm earned ($0.72) earnings per share. Chemomab Therapeutics Stock Performance Shares of CMMB stock […]

Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 37,400 shares, a decrease of 9.2% from the August 31st total of 41,200 shares. Based on an average daily volume of 56,700 shares, […]

Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 56,200 shares, a decline of 43.3% from the July 15th total of 99,200 shares. Approximately 0.5% of the shares of the company are […]

Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 56,200 shares, a decline of 43.3% from the July 15th total of 99,200 shares. Approximately 0.5% of the shares of the stock are sold short. Based […]